4.8 Article

Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1101756108

Keywords

-

Ask authors/readers for more resources

Natural immunity against obligate and/or facultative intracellular pathogens is usually mediated by both humoral and cellular immunity. The identification of those antigens stimulating both arms of the immune system is instrumental for vaccine discovery. Although high-throughput technologies have been applied for the discovery of antibody-inducing antigens, few examples of their application for T-cell antigens have been reported. We describe how the compilation of the immunome, here defined as the pool of immunogenic antigens inducing T-and B-cell responses in vivo, can lead to vaccine candidates against Chlamydia trachomatis. We selected 120 C. trachomatis proteins and assessed their immunogenicity using two parallel high-throughput approaches. Protein arrays were generated and screened with sera from C. trachomatis-infected patients to identify antibody-inducing antigens. Splenocytes from C. trachomatis-infected mice were stimulated with 79 proteins, and the frequency of antigen-specific CD4(+)/IFN-gamma(+) T cells was analyzed by flow cytometry. We identified 21 antibody-inducing antigens, 16 CD4(+)/IFN-gamma(+)-inducing antigens, and five antigens eliciting both types of responses. Assessment of their protective activity in a mouse model of Chlamydia muridarum lung infection led to the identification of seven antigens conferring partial protection when administered with LTK63/CpG adjuvant. Protection was largely the result of cellular immunity as assessed by CD4(+) T-cell depletion. The seven antigens provided robust additive protection when combined in four-antigen combinations. This study paves the way for the development of an effective anti-Chlamydia vaccine and provides a general approach for the discovery of vaccines against other intracellular pathogens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination

Paola Adele Lonati, Caterina Bodio, Mariangela Scavone, Giuliana Martini, Elisa Pesce, Alessandra Bandera, Andrea Lombardi, Maria Gerosa, Franco Franceschini, Angela Tincani, Gianmarco Podda, Sergio Abrignani, Renata Grifantini, Marco Cattaneo, Maria Orietta Borghi, Pier Luigi Meroni

Summary: The study found that COVID-19 vaccination does not affect the production of anti-PF4 antibodies and their ability to cause platelet activation in aPL-positive patients.

RMD OPEN (2022)

Article Oncology

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

Alessio Amatu, Arianna Pani, Giorgio Patelli, Oscar M. Gagliardi, Marina Loparco, Daniele Piscazzi, Andrea Cassingena, Federica Tosi, Silvia Ghezzi, Daniela Campisi, Renata Grifantini, Sergio Abrignani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi

Summary: This study evaluated the seroconversion rate of anti-spike antibodies in solid tumor patients after receiving SARS-CoV-2 mRNA vaccines and found a lower conversion rate in cancer patients. Age and treatment type also had an impact on the conversion rate. It is suggested to consider enhanced vaccination strategies for this group of patients and closely monitor SARS-CoV-2 infection during treatment.

EUROPEAN JOURNAL OF CANCER (2022)

Correction Medicine, General & Internal

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study (vol 9, 850858, 2022)

Ennio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, Gabriella Maioli, Martina Biggioggero, Elisa Pesce, Andrea Favalli, Martina Martinovic, Tanya Fabbris, Edoardo Marchisio, Alessandra Bandera, Andrea Gori, Sergio Abrignani, Renata Grifantini, Roberto Caporali

FRONTIERS IN MEDICINE (2022)

Article Medicine, General & Internal

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Ennio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, Gabriella Maioli, Martina Biggioggero, Elisa Pesce, Andrea Favalli, Martina Martinovic, Tanya Fabbris, Edoardo Marchisio, Alessandra Bandiera, Andrea Gori, Sergio Abrignani, Renata Grifantini, Roberto Caporali

Summary: This study evaluated the seroprevalence of SARS-CoV-2 antibodies in rheumatic musculoskeletal disease patients receiving immunomodulatory drugs. The overall prevalence of anti-SARS-CoV-2 antibodies was higher in these patients compared to laboratory positivity rate or clinically suspected cases, but similar to the healthy population. Glucocorticoids and comorbidities resulted in higher seroprevalence rate.

FRONTIERS IN MEDICINE (2022)

Meeting Abstract Rheumatology

IMMUNE RESPONSE TO SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATIC MUSCULOSKELETAL DISEASES: THE MAINSTREAM STUDY

E. G. Favalli, A. Favalli, G. Andrea, G. Maioli, E. Zagato, M. Bombaci, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M. L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notabartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Multidisciplinary Sciences

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

John E. Bowen, Amin Addetia, Ha Dang, Cameron Stewart, Jack T. Brown, William K. Sharkey, Kaitlin R. Sprouse, Alexandra C. Walls, Ignacio G. Mazzitelli, Jennifer K. Logue, Nicholas M. Franko, Nadine Czudnochowski, Abigail E. Powell, Exequiel Jr Dellota Jr, Kumail Ahmed, Asefa Shariq Ansari, Elisabetta Cameroni, Andrea Gori, Alessandra Bandera, Christine M. Posavad, Jennifer M. Dan, Zeli Zhang, Daniela Weiskopf, Alessandro Sette, Shane Crotty, Najeeha Talat Iqbal, Davide Corti, Jorge Geffner, Gyorgy Snell, Renata Grifantini, Helen Y. Chu, David Veesler

Summary: The Omicron variant of concern, characterized by numerous spike mutations, exhibits enhanced binding to ACE2, reduced fusogenicity, and reduced neutralizing activity against plasma induced by infection or vaccines. However, booster doses based on the Wuhan-Hu-1 spike sequence significantly increase neutralizing antibody titers and breadth against multiple Omicron sublineages.

SCIENCE (2022)

Article Immunology

Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers

Maria Orietta Borghi, Mauro Bombaci, Caterina Bodio, Paola Adele Lonati, Andrea Gobbini, Mariangela Lorenzo, Erminio Torresani, Antonella Dubini, Ilaria Bulgarelli, Francesca Solari, Francesca Pregnolato, Alessandra Bandera, Andrea Gori, Gianfranco Parati, Sergio Abrignani, Renata Grifantini, Pier Luigi Meroni

Summary: Molecular mimicry between SARS-CoV-2 and human proteins may result in autoimmunity during COVID-19. Vaccination does not induce early autoimmune response but occasionally leads to low levels of autoantibodies.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells

Michele Tomasi, Elena Caproni, Mattia Benedet, Ilaria Zanella, Sebastiano Giorgetta, Mattia Dalsass, Enrico Koenig, Assunta Gagliardi, Laura Fantappie, Alvise Berti, Silvia Tamburini, Lorenzo Croia, Gabriele Di Lascio, Erika Bellini, Silvia Valensin, Giada Licata, Guido Sebastiani, Francesco Dotta, Federica Armanini, Fabio Cumbo, Francesco Asnicar, Aitor Blanco-Miguez, Eliana Ruggiero, Nicola Segata, Guido Grandi, Alberto Grandi

Summary: A growing body of evidence supports the important role of the gut microbiome in cancer immunity, and it has been found that microbiome proteins can induce specific T cells, which can inhibit tumor growth. Furthermore, personalized mucosal cancer vaccines can be developed using engineered microbes and Outer Membrane Vesicles.

FRONTIERS IN ONCOLOGY (2022)

Article Medicine, General & Internal

Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2

Annarita Miluzio, Alessandro Cuomo, Chiara Cordiglieri, Lorena Donnici, Elisa Pesce, Mauro Bombaci, Matteo Conti, Alessandra Fasciani, Luigi Terracciano, Lara Manganaro, Mirco Toccafondi, Alessandra Scagliola, Stefania Oliveto, Sara Ricciardi, Renata Grifantini, Raffaele De Francesco, Sergio Abrignani, Nicola Manfrini, Stefano Biffo

Summary: The study found that the binding of the SARS-CoV-2 virus to hACE2 receptors is the first step in infection, but the abundance of receptors is influenced by various factors. Further research revealed SLC1A5 as a factor involved in receptor localization and viral entry, and co-expression with hACE2 improved the prediction of SARS-CoV-2 binding and entry. The Omicron variant showed higher efficiency in binding to hACE2 sites, but was equally sensitive to SLC1A5 downregulation.

EBIOMEDICINE (2023)

Article Immunology

Maturation of Aluminium Adsorbed Antigens Contributes to the Creation of Homogeneous Vaccine Formulations

Donatello Laera, Camilla Scarpellini, Simona Tavarini, Barbara Baudner, Agnese Marcelli, Carlo Pergola, Malte Meppen, Derek T. O'Hagan

Summary: Although aluminium-based vaccines have been used for a long time, their mechanism of action is still unclear. Antigen adsorption to the adjuvant facilitates delivery of the antigen to immune cells. Understanding the interactions between aluminium and antigens, as well as antigen distribution over the adjuvant particles, is crucial for further research.

VACCINES (2023)

Article Biochemistry & Molecular Biology

Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation

Lisa Pagani, Clizia Chinello, Giulia Risca, Giulia Capitoli, Lucrezia Criscuolo, Andrea Lombardi, Riccardo Ungaro, Davide Mangioni, Isabella Piga, Antonio Muscatello, Francesco Blasi, Andrea Favalli, Martina Martinovic, Andrea Gori, Alessandra Bandera, Renata Grifantini, Fulvio Magni

Summary: By studying the plasma proteome of 43 COVID-19 patients, differentially expressed proteins related to the severity of infection were identified. Three proteins were found to be able to accurately distinguish different stages of infection. These proteins may be associated with the severity of the disease and the immune response.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

TMEM123 a key player in immune surveillance of colorectal cancer

Elisa Pesce, Chiara Cordiglieri, Mauro Bombaci, Serenella Eppenberger-Castori, Stefania Oliveto, Cristina Manara, Mariacristina Crosti, Caner Ercan, Mairene Coto, Andrea Gobbini, Susanna Campagnoli, Tiziano Donnarumma, Manuele Martinelli, Valeria Bevilacqua, Elisa De Camilli, Paola Gruarin, Maria L. Sarnicola, Elisa Cassinotti, Ludovica Baldari, Giuseppe Viale, Stefano Biffo, Sergio Abrignani, Luigi M. Terracciano, Renata Grifantini

Summary: Colorectal cancer (CRC) is a major cause of cancer-related death. The interplay between effector immune cells and cancer cells in the tumor site plays a key role in determining tumor elimination or outgrowth. TMEM123 protein is over-expressed in infiltrating CD4 and CD8 T lymphocytes and contributes to their effector phenotype. TMEM123 plays a role in lymphocyte migration and cytoskeleton organization, and its presence is associated with improved survival in CRC patients.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype

Ylenia Silvestri, Francesca Clemente, Giorgia Moschetti, Sara Maioli, Elena Carelli, Alejandro Espadas de Arias, Rosanna Torelli, Elena Longhi, Tullia De Feo, MariaCristina Crosti, Maria Lucia Sarnicola, Mario Salvi, Giovanna Mantovani, Maura Arosio, Mauro Bombaci, Elisa Pesce, Renata Grifantini, Sergio Abrignani, Jens Geginat, Ilaria Muller

Summary: SARS-CoV-2 infection can lead to thyroid disorders like subacute thyroiditis (SAT). This study aimed to investigate the role of T-cells in SAT following severe COVID disease (COV-A-SAT). T-cells from COV-A-SAT patients were analyzed and compared to controls. The results showed that COV-A-SAT was associated with specific HLA haplotypes and activated T-cell responses. Tissue-resident memory cells were present in the thyroid, suggesting a prolonged immune response in the target tissue.

CLINICAL IMMUNOLOGY (2023)

Article Immunology

Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid Protein L2

Silvia Tamburini, Yueru Zhang, Assunta Gagliardi, Gabriele Di Lascio, Elena Caproni, Mattia Benedet, Michele Tomasi, Riccardo Corbellari, Ilaria Zanella, Lorenzo Croia, Guido Grandi, Martin Mueller, Alberto Grandi

Summary: This study demonstrates that L2 epitopes can be efficiently expressed on the surface of E. coli outer membrane vesicles (OMVs), and a polypeptide composed of L2 epitopes from multiple serotypes shows broad cross-protective activity against HPV. This provides a highly effective and inexpensive solution for producing universal anti-HPV vaccines.

VACCINES (2023)

Article Immunology

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine

Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari, Gabriele Di Lascio, Silvia Tamburini, Elena Caproni, Lorenzo Croia, Micol Rava, Valeria Fumagalli, Pietro Di Lucia, Davide Marotta, Eleonora Sala, Matteo Iannacone, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Peter Cherepanov, Martino Bolognesi, Massimo Pizzato, Guido Grandi

Summary: The study demonstrates that engineered OMVs vaccines can induce effective immune responses, producing neutralizing antibodies and protecting animals from SARS-CoV-2 infection. Furthermore, the vaccine can also elicit immune responses against the Omicron BA.1 and BA.5 variants. OMV-based SARS-CoV-2 vaccines, with the convenience of engineering, production, and distribution, can be a crucial addition to the currently available vaccines.

VACCINES (2023)

No Data Available